Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.

Integrative cancer therapies - 1 Jan 2026

Kim Daeun, Kim Young-Ha, Choi Gaeun, Cheon Chunhoo, Ko Seong-Gyu

Abstract excerpt

IntroductionFirst-generation EGFR-TKIs in NSCLC frequently lose efficacy as a result of the secondary EGFR-T790M mutation and a "persistent-STAT3" prosurvival pathway that sustains STAT3-survivin signaling in the face of EGFR inhibition. Preclinical evidence demonstrates that phytochemicals in the JI017 herbal formulation (2:1:1, Angelica gigas: processed Aconitum carmichaeli: Zingiber officinale) can reinstate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Carcinoma, Non-Small-Cell Lung
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Protein Kinase Inhibitors

Share to STAT3 Transcription Factor

Share to Survivin

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42549682
DOI: 10.1177/15347354261475694
PMCID: PMC13438235

Genes

EGFR
STAT3
AXL
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.PMID 42549682Read ↗

Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK/AKT/STAT3 Signaling.Semantic proximity Read ↗

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.Semantic proximity Read ↗

HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair.Semantic proximity Read ↗

HBE-843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.Semantic proximity Read ↗

Gracillin overcomes osimertinib resistance in NSCLC via dual inhibition of EGFR and Mcl-1.Semantic proximity Read ↗

Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.Semantic proximity Read ↗

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.Semantic proximity Read ↗

BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.Semantic proximity Read ↗

Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation.Semantic proximity Read ↗

Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway.Semantic proximity Read ↗

Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.